Tim Davis
Regional Head, UK Primary Markets at London Stock Exchange Group
Tim Haines
Executive Partner at AbingworthTim has more than 30 years of international management experience in the life sciences industry in both public and private companies. During his time at Abingworth Tim has taken Chair and board roles in a number of companies including Astex, Fovea, GammaDelta Therapeutics, MEDIAN Technologies, PowderMed, Sientra, Scorpion, Venatorx and Adaptate Biotherapeutics.
Before joining Abingworth in 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for over five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc and General Manager Baxter UK. Tim has a BSc from Exeter University and an MBA from INSEAD. He is on the Investment Advisory Board of Oxford University Innovation and is a former Director of the BIA, the BVCA Venture Committee and sat on the Wellcome Trust / NHS Health Innovation Challenge Fund.
Patrik Frei
CEO of Venture Valuation
Catherine Bacon
CEO of FingerPost
Jenny Bailey Cooper
CEO of Ferryx
Emma Thorp
Founder & Coach of Thorp CoachingEmma is the Founder of Thorp Coaching, where she empowers leaders to achieve their goals while staying true to purpose, connection, and joy. With decades of leadership experience, including roles as Chief Commercial Officer and founder of a successful consulting business.
As Co-Founder of the Diverse Directors Programme, Emma champions diversity in boardrooms, preparing underrepresented leaders for Non-Executive Director roles. Her nature-inspired, intuitive coaching approach helps leaders navigate challenges and develop winning mindsets. On the panel “The Humble CEO – What Makes a Winning Mindset”, Emma will explore fostering resilience, embracing humility, and unlocking purpose-led leadership.
Bharat Chudasama
Vice President, Head of Strategic Partnerships at Syneos Health
Francesca Cordeiro
Founder & CEO of NovaiProfessor M Francesca Cordeiro, is a clinician-scientist, Chair of Ophthalmology Imperial College London, and UCL Professor, Honorary Consultant Ophthalmologist/Research Lead, Director of the ICORG Clinical Trials Unit at the Western Eye Hospital London, and recently Founder and Director of Novai Ltd, a start-up company based on DARC Technology.
Her research, funded continuously by the Wellcome Trust since 1996, focuses on novel and translational approaches with a target of saving sight and reducing disability, with over 180 peer-reviewed publications.
She has received a number of international awards for this work, including the Lewis Rudin Glaucoma Prize 2005, the Research to Prevent Blindness International Research Scholar Award 2015, the GG2 Diversity Award for Outstanding Achievement in Medicine 2017 and 2019 Duke Elder Award (Royal College of Ophthalmologists) and is frequently asked to give keynote lectures abroad.
Simon Bornschein
Founder & Chief Executive Officer of Coding Bio
Andrew Craig
Founder of Plain English Finance
Peter Dines
Managing Director of Mercia Ventures
William Finch
CEO of Oxford Vacmedix UKAfter graduating from Oxford in Biochemistry William has over 34 years experience in the Biotech sector with a particular focus on leading SMEs.
Previous companies include R&D Systems, Amersham International, British Biotech and Beckman Coulter alongside small start-ups following outsourcing strategies where relevant.
James Fry
Partner - Head of Life Sciences at Mills and Reeve LLPJames is a partner at the law firm Mills & Reeve and heads the firm's life sciences sector. James is an experienced commercial and IP transactions lawyer with significant experience across the life sciences, including biotech, pharma and medical technologies. He regularly advises biotech and biopharma organisations on out-licensing and in-licensing transactions, broader partnering transactions, and on product development and commercialisation.
KIRAN GULATI
Director, Business Operations of New England Biolabs (UK)
Jonathan Heeney
Founder & Chief Executive Officer of DIOSynVax
Jacob Hurst
Co-Founder & Chief Technology Officer of EtcemblyJacob Hurst, is the co-founder and CTO of Etcembly. Within Etcembly he helped pioneer the informatics techniques that have resulted in Etcembly being the second company in the world to affinity enhance a TCR to pM level and the first company to do so entirely by informatics. He holds a PhD in Machine Learning, and has worked with biological data since 2002.
Jacob has worked as a scientific researcher at University College London and University of Oxford. and has co-authored over 50 scientific papers with a deep knowledge of antibodies and TCRs.
Kath Mackay
Director of Life Sciences at Bruntwood SciTechDr Kath Mackay is Director of Life Sciences for Bruntwood SciTech - the UK’s leading property provider dedicated to driving the growth of the UK science and technology sector. She has a keen interest in growing the life science industry, and businesses and infrastructure within the sector, ensuring the UK is the best place to establish and scale a life science organisation.
As Director of Life Sciences, Kath is responsible for developing the life science vision and strategy for Bruntwood SciTech, external affairs, and developing sector specific innovation services and investment support for the life sciences business across our network of campuses. Kath also oversees Alderley Park - the UK’s largest single- site life science campus - the new £210m Birmingham Health Innovation Campus, and Citylabs in Manchester, the world-leading health innovation and precision medicine campus in partnership with Manchester University NHS Foundation Trust.
Kath joined Bruntwood SciTech from the executive board of Innovate UK where she led the team responsible for growing and scaling businesses working in the biomedical, health, agriculture and food sectors, creating and delivering a £700m portfolio of infrastructure, Catapults, grant and loan investments. Kath is also Non-Executive Director of the Northern Health Science Alliance, the North of England’s health partnership, UKRI’s National Biofilms Innovation Centre, and Cheshire and Warrington Local Enterprise Partnership.
Michael Malecki
President & CEO of Apex Market Access
Damian Marron
Head of Biopharma at Treehill Partners Ltd
Gino Martini
CEO of Precision Health Technologies Accelerator Ltd (PHTA)
Jon Rees
Co-Founder & Senior Discovery Scientist of MitoRx Therapeutics
Nik Sharma
Co-Founder CEO of BioCorteX
Nadia Shivji-Brown
Senior Business Development Manager at UK Health Security Agency
Mihriban Tuna
CEO of ImmutrinMihriban is an executive leader with over 20 years’ experience in biologics drug development across biotech and pharma. She is currently CEO of Immutrin and Entrepreneur in Residence at Cambridge Innovation Capital.
Previously, Mihriban was Chief Scientific Officer at Adaptate Biotherapeutics (acquired by Takeda), Senior Vice President of Drug Discovery at F-star Therapeutics and an early employee at Domantis (acquired by GSK).
Mihriban holds a BSc in Biology from Middle East Technical University, a PhD in Biochemistry from University of Sussex and an EMBA from University of Cambridge Judge Business School.
Mel Walker
Managing Director of BioPharma Futures
David Weinkove
CSO at Magnitude BiosciencesDavid Weinkove has worked in the field of ageing for over 25 years and is the Chair of the British Society for Research on Ageing. He is also a Professor in the Department of Biosciences at Durham University, where he researches how bacteria impact ageing using the nematode worm C. elegans as a fast-ageing in vivo model. In 2018, David co-founded Magnitude Biosciences to apply to the power of the C. elegans and automated imaging technology to industrial drug discovery. As Chief Scientific Officer, David helps clients find solutions to their drug discovery challenges using C. elegans where possible.